康弘药业：子公司收到KH813注射液临床试验批准通知书

Group 1 - The company announced that its wholly-owned subsidiary, Chengdu Kanghong Biotechnology Co., Ltd., received the clinical trial approval notice for KH813 injection from the National Medical Products Administration [1] - KH813 injection is a biosimilar of Pembrolizumab developed by Kanghong Biotechnology, primarily used for the treatment of various advanced solid tumors [1] - The approval indicates progress in the company's drug development pipeline, although drug development carries inherent uncertainties [1]